The mystical effects of dermatological vehicles

Dermatology

Volumn 210, Issue 2, 2005, Pages 157-168

  Surber, Christian ^a,c   Smith, Eric W ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Topical dermatological vehicles, evolution; Vehicle metamorphosis

Indexed keywords

ANALGESIC AGENT; ANTIPRURITIC AGENT; ASTRINGENT AGENT; BETAMETHASONE DIPROPIONATE; CHLORAMPHENICOL; DRUG VEHICLE; ETHOSOME; LIPOSOME; NANOPARTICLE; PHENYTOIN; PROPYLENE GLYCOL; SOLID LIPID NANOPARTICLE; TRANSFERSOME; UNCLASSIFIED DRUG;

COSMETIC INDUSTRY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RETENTION; ENVIRONMENTAL FACTOR; HUMAN; METAMORPHOSIS; MICROEMULSION; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN INJURY;

ADMINISTRATION, CUTANEOUS; DERMATOLOGIC AGENTS; HUMANS; SKIN DISEASES; VEHICLES;

EID: 16244372385     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082572     Document Type: Review

References (85)

1. Humbel UM: Zur Geschichte der Antimykotika in der zweiten Hälfte des 19. Jahrhunderts. Dietikon, Juris Druck + Verlag, 1993.
2. Peiner L: Paul Gerson Unna. NY State J Med 1971;12:2895-2896.
3. Braun-Falco O: Geschichte der Dermatologie: 100 Jahre äusserliche Behandlung von Hautkrankheiten: Von der Empirie zur pharmakologisch begründeten Dermatotherapie. Hautarzt 1975;26:374-377.
4. Hollander A: Betrachtungen über Paul Gerson Unna. Z Hautkr 1984;59:680-687.
5. Hollander AW: Development of dermatopathology and Paul Gerson Unna. J Am Acad Dermatol 1986;15:727-734.
6. Fleischer R: Untersuchungen über das Resorptionsvermögen der menschlichen Haut. Erlangen, Eduard Besold, 1877.
7. Bourget: Über die Resorption der Salicylsäure durch die Haut und die Behandlung des acuten Gelenkrheumatismus. Ther Monatsh 1893;7:531-539.
8. Schwenkenbecher A: Das Absorptionsvermögen der Haut. Arch Anat Physiol 1904;1-2:121-127.
9. Reynolds HJ: Eine Methode zur Behandlung der Pilzkrankheiten der Haut. Monatsh Prakt Dermatol 1887;6:945-949.
10. Leduc S: Introduction des substances médicamenteuses dans la profondeur des tissues par le courant électrique. Ann Electrobiol 1900;3:545-560.
11. Turrell WJ: The therapeutic action of the constant current. Proc R Soc Med 1921;14:41-52.
12. Licht S: History of electrotherapy, in Licht S (ed): Therapeutic Electricity and Ultraviolet Radiation. New Haven, Licht, 1967, pp 1-70.
13. Chien YW, Banga AK: Iontophoretic (transdermal) delivery of drugs: Overview of historical development. J Pharm Sci 1989;78:353-354.
14. Porjé IG: En Studie över sorbiddinitratets perkutana resorption. Svenska Läkartidningen 1946;44:923-925.
15. Davis TA, Wiesel BH: The treatment of angina pectoris with a nitroglycerin ointment. Am J Med Sci 1955;230:259-263.
16. Zaffaroni A: Therapeutic adhesive patch. US Patent 3,699,963. 1972 18.
17. Zaffaroni A: Bandage for the administration of drug by controlled metering through microporous materials. US Patent 3,797,494. 1974 8.
18. Shaw J, Urquhart J: Programmed, systemic drug delivery by the transdermal route. Trends Pharm Sci 1980;1:208-211.
19. Urquhart J: Rate-controlled drug dosage. Drugs 1982;23:207-226.
20. Newbold PCH, Stoughton RB: Percutaneous absorption of methotrexate. J Invest Dermatol 1972;58:319-322.
21. Laugier J-P, Surber C, Bun H, Geiger J-M, Wilhelm K-P, Durand A, Maibach HI: Determination of acitretin in the skin, in the suction blister, and in plasma of human volunteers after multiple oral dosing. J Pharm Sci 1994;83:623-628.
22. Surber C, Itin P, Büchner S: Clinical controversy on the effect of topical ciclosporin A: What is the target organ? Dermatology 1992;185:242-245.
23. Parry GE, Dunn P, Shah VP, Pershing LK: Acyclovir bioavailability in human skin. J Invest Dermatol 1992;98:856-863.
24. Imanidis G, Song W, Lee PH, Su MH, Kern ER, Higuchi WI: Estimation of skin target site acyclovir concentrations following controlled (trans)dermal drug delivery in topical and systemic treatment of cutaneous HSV-1 infections in hairless mice. Pharm Res 1994;11:1035-1041.
25. Samson C, Peets E, Winter-Sperry R, Wolkoff H: Augmented betamethasone dipropionate - Diprolene® - enhancement of topical activity through vehicle formulation; in Maibach HI, Surber C (eds): Topical Corticosteroids. Basel, Karger, 1992, pp 302-317.
26. Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H: Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993;10:1738-1744.
27. Gabard B, Treffel P: Skin penetration and sun protection factor of ultra-violet filters from two vehicles. Pharm Res 1996;13:770-774.
28. Zhai H, Willard P, Maibach HI: Evaluating skin protective materials against contact irritants and allergens. Contact Dermatitis 1998;38:155-158.
29. FDA, Center of Drug Evaluation and Research: Guidance: Topical dermatologic corticosteroids: In vivo bioequivalence. Rockville, Division of Bioequivalence, June 2, 1995.
30. European Commission: CPMP Efficacy Working Party: Clinical requirements for locally applied, locally acting products, containing known constituents. CPMP/EWP/239/95, Final. November 1995.
31. BGA: Bekanntmachung über die Zulassung und Registrierung und über die Verlängerung der Zulassung von Arzneimitteln nach Artikel 3&7 des Gesetzes zur Neuordnung des Arzneimittelrechts (Besonderheiten zu topischen Arzneimitteln). 1992.
32. BGA: Diskussionspapier zur Bewertung topischer Antirheumatika. Bundesgesundheitsbl 1991;2:78.
33. Flynn GL: Topical drug absorption and topical pharmaceutical systems; in Banker GS, Rhodes CT (eds): Modern Pharmaceutics. New York, Dekker, 1990, pp 263-325.
34. Clark R: Cosmetic creams and lotions; in Hibbott HW (ed): Handbook of Cosmetic Science: An Introduction to Principles and Applications. Oxford, Pergamon, 1963, pp 257-294.
35. Sherman P: Consistency profiling, and evaluation of pharmaceutical products. Rheol Acta 1971;10:121-126.
36. Griffiths WAD, Wilkinson JD: Topical therapy; in Champion RH, Burton JL, Ebling FJG (eds): Rook, Wilkinson, Ebling Textbook of Dermatology. London, Blackwell Scientific, 1992, pp 3037-3084.
37. Thoma K: Dermatika. München, Werbe- und Vertriebsgesellschaft Deutscher Apotheker, 1983.
38. Müller KH: Systematik der Externa. Fette Seifen Anstrichmittel 1979;81:133-136.
39. Katz M: Design of topical drug products: Pharmaceutics, in Ariëns EJ (ed): Drug Design. New York, Academic Press, 1973, pp 93-148.
40. Juch RD, Rufli T, Surber C: Pastes: What do they contain? How do they work? Dermatology 1994;189:373-377.
41. Smith EW, Surber C, Tassopoulous T, Maibach HI: Topical dermatological vehicles: A holistic approach; in Bronaugh RL, Maibach HI (eds): Topical Absorption of Dermatological Products. New York, Dekker, 2002, pp 457-463.
42. Polano MK: Topical Skin Therapeutics. Edinburgh, Churchill Livingstone, 1984.
43. Lorincz AL: The pharmacology of topically applied medications; in Sternberg TH, Newcomer VD (eds): The Evaluation of Therapeutic Agents and Cosmetics. New York, McGraw-Hill, 1964, pp 86-94.
44. Heisel EW: Principles of local dermatologic therapy; in Criep LH (ed): Dermatologic Allergy: Immunology, Diagnosis and Management. Philadelphia, Saunders, 1967, pp 540-558.
45. Obata M, Tagami H: A rapid in vitro test to assess skin moisturizers. J Soc Cosmet Chem 1990;41:235-241.
46. Fowler JF: Disulfiram is effective for nickel allergic hand eczema. Am J Contact Dermatitis 1992;3:175-178.
47. Wolf R: Has mildness replaced cleanliness next to godliness? Dermatology 1994;189:217-221.
48. Hills RJ, Unsworth A, Ive FA: A comparative study of the frictional properties of emollient bath additives using porcine skin. Br J Dermatol 1994;130:37-41.
49. Gabard B: Testing the efficacy of moisturizers; in Elsner P, Berardesca E, Maibach HI (eds): Bioengineering of the Skin: Water and Stratum corneum. Boca Raton, CRC Press, 1994, pp 147-170.
50. Lalor CB, Flynn GL, Weiner N: Formulation factors affecting release of drug from topical vehicles. II. Effect of solubility in in vitro delivery of a series of n-alkyl p-aminobenzoates. J Pharm Sci 1995;84:673-676.
51. Ferreira LAM, Doucet J, Seiller M, Grossiord JL, Marty JP, Wepierre J: In vitro percutaneous absorption of metronidazole and glucose: Comparison of o/w, w/o/w and w/o systems. Int J Pharm 1995;121:169-179.
52. Ferreira LAM, Seiller M, Grossiord JL, Marty JP, Wepierre J: Vehicle influence on in vitro release and percutaneous absorption of glucose: Role of w/o/w multiple emulsion. Proc Int Symp Control Rel Bioact Mater 1994;21:453-454.
53. Friedman DI, Schwarz JS, Weisspapir M: Submicron emulsion vehicle for enhanced transdermal delivery of steroidal antiinflammatory drugs. J Pharm Sci 1995;84:324-329.
54. Gollnick HP, Krautheim A: Topical treatment in acne: current status and future aspects. Dermatology 2003;206:29-36.
55. Kondo S, Yamanaka C, Sugimoto I: Enhancement of transdermal delivery by superfluous thermodynamic potential. III. Percutaneous absorption of nifedipine in rats. J Pharmacobiodyn 1987;10:743-749.
56. Megrab NA, Williams AC, Barry BW: Oestradiol permeation through human skin and Silastic membrane: Effects of propylene glycol and supersaturation. J Contr Rel 1995;36:277-294.
57. Sato K, Sugibayashi K, Morimoto Y: Effect of mode of action of aliphatic esters on the invitro skin penetration of nicorandil. Int J Pharm 1988;43:31-40.
58. Yamane MA, Williams AC, Barry BW: Effects of terpenes and oleic acid as skin penetration enhancers towards 5-fluorouracil as assessed with time: permeation, partitioning and differential scanning calorimetry. Int J Pharm 1995;116:237-251.
59. Danon A, Horowitz J, Ben-Zvi-Z: An outbreak of digoxin intoxication. Clin Pharmacol Ther 1977;21:643-646.
60. Melikian AP, Straughn AB, Slywka GWA, Whyatt PL, Meyer MC: Bioavailability of eleven phenytoin products. J Pharmacokinet Biopharm 1977;5:133-146.
61. Glazko AJ, Kinkel AW, Alegnani WC, Holmes EL: An evaluation of absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol 1968;9:472-483.
62. Cornell RC, Stoughton RB: Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-67.
63. Hundeiker M: Grundlagen der Therapie mit äusserlichen Arzneimittelzubereitungen. Zentralbl Hautkr 1982;148:683-697.
64. Schaefer H, Zesch A, Stüttgen G: Skin Permeability. Berlin, Springer, 1982.
65. Barry BW: Dermatologic Formulations. New York, Dekker, 1983.
66. Ive A, Comaish S: Topical therapy. Recent Adv Dermatol 1980;5:285-315.
67. Schlossmann ML: Formulating ethnic makeup products. J Cosmet Toilet 1995;110:59-63.
68. Sugino K, Imokawa G, Maibach HI: Ethnic difference of stratum corneum lipid in relation to stratum corneum function. J Invest Dermatol 1993;100:597-601.
69. Breuer K, Braeutigam M, Kapp A, Werfel T: Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004;209:314-320.
70. Lodén M: The increase in skin hydration after application of emollients with different amounts of lipids. Acta Derm Venereol (Stockh) 1992;72:327-330.
71. Choudhury TH, Marty JP, Orecchini AM, Seiller M, Wepierre J: Factors in the occlusivity of aqueous emulsions: Influence of humectants. J Soc Cosmet Chem 1985;36:255-269.
72. 14C cortisol in man. J Invest Dermatol 1967;48:181-183.
73. Maibach HI, Feldmann RJ, Milby TH, Serat WF: Regional variation in percutaneous penetration in man. Arch Environ Health 1971;23:208-211.
74. Lynfield YL, Schlechter S: Choosing and using a vehicle. J Am Acad Dermatol 1984;10:56-59.
75. Loesch H, Kaplan DL: Pitfalls in sunscreen application. Arch Dermatol 1994;130:665-666.
76. Meyer E, Smith EW, Haigh JM: Sensitivity of different areas of the flexor aspect of the human forearm to corticosteroid-induced skin blanching. Br J Dermatol 1992;127:379-381.
77. Shuster S: Understanding skin disease. Triangle 1987;26:125-138.
78. Grimm W: International harmonization of stability tests for pharmaceuticals: The ICH tripartite guideline for stability testing of new drug substances and products. Eur J Pharm Biopharm 1995;41:194-196.
79. Chiang C-M, Flynn GL, Weiner ND, Szpunar GJ: Bioavailability assessment of topical delivery systems: Effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations. Int J Pharm 1989;55:229-236.
80. Davis AF, Hadgraft J: Effect of supersaturation on membrane transport. 1. Hydrocortisone acetate. Int J Pharm 1991;76:1-8.
81. Meidan V, Alhaique F, Touitou E: Vesicular carriers for topical delivery. Acta Technol Legis Med 1998;9:1-6.
82. Lehmann L, Keipert S, Gloor M: Effects of microemulsions on the stratum corneum and hydrocortisone penetration. Eur J Pharm Biopharm 2001;52:129-136.
83. Begona Delgado-Charro M, Iglesias-Vilas G, Blanco-Méndez J, Arturo López-Quintela M, Marty J-P, Guy RH: Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur J Pharm Biopharm 1997;43:37-42.
84. Wissing SA, Muller RH: Solid lipid nanoparticles as carriers for sunscreens: In vitro release and in vivo skin penetration. J Control Rel 2002;81:225-233.
85. Muller RH, Radtke M, Wissing SA, et al: Solid lipid nanoparticles and nanostructured lipid carriers in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54(suppl 1): S131-S155.